Evidence map›Paper›PMID 18281734›Full record

Trial reportAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists2008

Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir.

Hiba L Tappouni, John C Rublein, Brian J Donovan, Stephanie B Hollowell, Hsiao-Chuan Tien, Sherene S Min, Dickens Theodore, Naser L Rezk, Philip C Smith, Melanie N Tallman and 2 more

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 28 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Hiba L TappouniDivision of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina, Chapel Hill 27599-7360, USA.
John C Rublein
Brian J Donovan
Stephanie B Hollowell
Hsiao-Chuan Tien
Sherene S Min
Dickens Theodore
Naser L Rezk
Philip C Smith
Melanie N Tallman
Ralph H Raasch
Angela D M Kashuba
University of North Carolina at Chapel Hill · USCubist Pharmaceuticals (United States) · USGlaxoSmithKline (India) · INGlaxoSmithKline (United Kingdom) · GBUniversity of North Carolina Health Care · USWillis-Knighton Cancer Center · US

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Zonisamide in Patients with Neuropathic Pain Associated with Diabetic NeuropathyM01RR000046 · NCRR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOY, MELANIE S · 1985 to 2008
$38.5M
NCRR NIH HHS M01 RR000046NIAID NIH HHS P30 AI050410
6 · The paper itself

Abstract

purposeThe effects of omeprazole on indinavir when administered alone or in combination with ritonavir were evaluated.

methodsFourteen men and women age 18-55 years not infected with human immunodeficiency virus who met study qualifications were randomized to receive placebo, 20 mg of omeprazole, or 40 mg of omeprazole daily. After seven days, the single-dose pharmacokinetic profile of an 800-mg dose of indinavir alone or in combination with 200 mg of ritonavir was evaluated. Study participants received each of four study regimens in one of four randomly assigned orders. Blood samples were collected, and plasma indinavir and ritonavir concentrations were analyzed using high-performance liquid chromatography.

resultsThe coadministration of 20 or 40 mg of omeprazole with indinavir significantly reduced the mean indinavir area under the concentration-versus-time curve (AUC) from 30.0 mg x hr/L (95% confidence interval [CI], 21.9-41.1 mg x hr/L) to 19.7 mg x hr/L (95% CI, 14.6-26.8 mg x hr/L) or 16.0 mg x hr/L (95% CI, 11.8-21.7 mg x hr/L), respectively (p < 0.002). The addition of 200 mg of ritonavir to 800 mg of indinavir in combination with 40 mg of omeprazole significantly increased the mean indinavir AUC from 30.0 mg x hr/L (95% CI, 21.9-41.1 mg x hr/L) to 46.6 mg x hr/L (95% CI, 34.0-63.8 mg x hr/L), but it did not significantly affect mean omeprazole concentrations (p < or = 0.02).

conclusionThe AUC of indinavir was substantially decreased in healthy volunteers who received omeprazole 20 or 40 mg daily for seven days before the administration of a single 800-mg dose of indinavir. Concomitant administration of ritonavir 200 mg with indinavir in participants receiving omeprazole led to a significant increase in the AUC of indinavir.

Indexed as

AdolescentAdultAnti-Ulcer AgentsArea Under CurveChromatography, High Pressure LiquidDose-Response Relationship, DrugDrug InteractionsDrug Therapy, CombinationFemaleHIV Protease InhibitorsHumansIndinavirMaleMiddle AgedOmeprazoleRitonavirAnti-Ulcer AgentsHIV Protease InhibitorsIndinavirOmeprazoleRitonavir

Identifiers

PMID18281734
PMCPMC2746430
OpenAlexW2158992885

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.